At a glance
Read the record in context
The with-DAC form pairs an albumin-binding modification with an extended research reference. Its 2 mg catalog package is smaller than the no-DAC example, but package mass and modeled duration measure unrelated properties. The card preserves those separate units rather than implying a relationship between them.[1]
What the research says
The human CJC-1295 publication examined whether a long-acting GHRH analog could sustain growth hormone and IGF-I secretion. Two controlled studies enrolled healthy adults aged 21 to 61 years. Participants received subcutaneous injections, with single-administration and repeated-administration designs followed over 28 or 49 days.[2]
Investigators measured peak hormone concentrations, hormone exposure over time, and standard pharmacokinetic parameters for CJC-1295. The estimated compound half-life ranged from 5.8 to 8.1 days. Growth hormone and IGF-I were separate measured outcomes, each with its own response duration following administration.[2]
Repeated exposure produced evidence of a cumulative hormonal effect in that study population. The library uses approximately eight days as its timing reference, within the reported range. The paper concerns the long-acting CJC-1295 form; it cannot supply the missing human kinetics of a product described as CJC-1295 without DAC.[2][1]
Cited amounts
The library records 2 mg as a supplier catalog package amount. This is the total listed in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1][3]
Explore the CJC-1295 (with DAC) dosing chartHalf-life and timing
The stored 192 hours are equivalent to eight days. Two successive halvings span 16 days and leave 25%; five span 40 days and leave 3.125%. Those intervals are generated from a fixed reference without modeling absorption or additional administrations. The long axis reflects the library's with-DAC context. It is not evidence that a particular person has eliminated the compound by day 40, and it does not give the missing clinical information needed to choose an amount or interval.[1][5]
Explore the CJC-1295 (with DAC) half-life modelReconstitution
For a 2 mg package and an assumed 2 mL final liquid volume, the quotient is 1 mg/mL. That makes a hypothetical 0.1 mL equal to 0.1 mg, or 100 micrograms. The easily read numbers are chosen to explain the equation, not to reproduce a study design. Switching from milligrams to micrograms leaves the mass unchanged. A different sourced package or independently known liquid volume would require its own calculation, while retaining the with-DAC identity.[3]
Tracking it in PinPoint
From a reference to a record
Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]
The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.
Get PinPoint on the App StoreFrequently asked questions
- What does CJC-1295 with DAC mean in a peptide guide?
- It identifies the drug affinity complex modification discussed in the library's albumin-binding reference. This is the extended-duration entry, with 192 hours stored for modeling. The no-DAC guide covers a different, explicitly extrapolated reference context.[1][2]
- Is the CJC-1295 with DAC package the same as the no-DAC example?
- The library lists 2 mg for the with-DAC catalog package and 5 mg for the no-DAC example. Those are specific listings. A calculator needs the actual known total rather than assuming that similar compound names imply identical containers.[1][5]
- Does albumin-binding context change the conversion formula?
- It informs the research description and timing model, not the dimensional equation. Concentration remains mass divided by volume. An extended half-life cannot be inserted into that division to obtain a different concentration or select an administration amount.[1][5]
- Can a peptide tracker app record CJC-1295 (with DAC)?
- PinPoint's compound library includes CJC-1295 (with DAC). The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]
Sources
Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.
- PinPoint compound library, CJC-1295 (with DAC)Snapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
- PubMed pharmacology reference 16352683Identity and research summary checked against this document on 5 October 2026. PubMed abstract, retrieved through NCBI EFetch.Retrieved 2026-10-05 · library-reference
- Supplier catalog package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · supplier
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
- Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic